20
Participants
Start Date
September 15, 2025
Primary Completion Date
June 1, 2030
Study Completion Date
June 1, 2030
Everolimus
"The starting dose of EVR will be based on the maintenance TAC dose of the subject at study entry:~1. EVR 1 mg PO BID if TAC dose is \<=2 mg BID~2. EVR 2 mg PO BID if TAC dose is 2.5-7 mg BID~3. EVR 3 mg PO BID if TAC dose is \>7 mg BID~The dosage will be adjusted as needed to achieve and maintain EVR trough concentration of 5-8 ng/mL."
Epoetin alfa
The dose used in this study is 10,000 units SC every 8 weeks (at study weeks 16, 24, 32, 40 and 48) for five doses
University of Pennsylvania Medical Center, Philadelphia
Northwestern University Feinberg School of Medicine, Chicago
University of California San Francisco School of Medicine, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID)
NIH